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The aromatic amino acid hydroxylases (AAHs); phenylalanine hydroxylase (PAH), 
tyrosine hydroxylase (TH), tryptophan hydroxylase 1 and 2 (TPH 1/TPH 2); are 
structurally and functionally related enzymes. All AAHs require iron, dioxygen and the 
cofactor (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4) to be catalytically active. 
PAH is the first and rate-limiting enzyme in the catabolism of L-Phe; TH is the rate-
limiting enzyme in the synthesis of the catecholamine neurotransmitters dopamine, 
adrenaline and noradrenaline; while the TPH 1 and 2 catalyses the first and rate-
limiting reaction in then synthesis of serotonin and melatonin.  
These physiologically important enzymes are implicated in human diseases; 
polymorphisms and variants in the TPH genes are associated to neuropsychiatric 
disorders, mutations in PAH and TH are responsible for the autosomal recessive 
disorders phenylketonuria (PKU) and TH deficiency (THD), respectively. 
Furthermore, a role of TH in Parkinson’s disease and hypoxia induced diseases, such 
as altitude sickness and sleep apnoea, has been suggested. 
The aims of this project were to 1) develop improved methods of studying AAHs, 
mainly focusing on their dependence of oxygen; 2) investigate the role of oxygen in 
the AAH reactions, with an emphasis on TH; 3) to characterize the effect of mutations 
in AAH, mainly PAH and TH, on their enzyme function and stability; 4) investigate 
the effects of missense TH mutations reported in patients with THD and perform 
genotype-phenotype comparisons in these patients.  
The thesis is based on three separate articles (Article 1-3); the first article is focused on 
developing a new oxygrapic assay method for studying the activity and enzymatic 
mechanism of AAHs by monitoring the oxygen consumption continuously during the 
catalytic reaction. The second paper describes the oxygen dependence of TH in 
normoxic and hypoxic conditions, relevant for physiological effects of high altitude 
and other conditions of low oxygen availability. In the third article, mutated variants 
of TH reported in patients with THD, were characterized and compared to wild-type 
(wt)-TH with regards to in vitro solubility, thermal stability and kinetic properties.  
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In Article 1 we demonstrated the utility of a new oxygrapic assay to study the function 
of AAHs. We studied kinetic properties and enzyme reaction mechanisms of both wt 
and mutant enzyme using different substrates and cofactors. A stable reaction 
stoichiometry of 1:1 was obtained between the amount of oxygen consumed and 
tyrosine formation when the natural cofactor (6R)-tetrahydrobiopterin was added as 
electron donor in the phenylalanine hydroxylase (PAH) reaction. In comparison, low 
and variable coupling efficiency values between oxygen consumption and tyrosine 
formation were found using the parent unsubstituted tetrahydropterin. Furthermore, we 
studied the phenylketonuria-associated PAH mutant R158Q and found that the reaction 
had a coupling efficiency of about 80 % compared to the wild-type enzyme under 
similar conditions. The high time resolution of this method allowed us to obtain new 
knowledge about the initial reaction kinetics of the AAHs.  
These findings were investigated further in Article 2; where we observed an initial high 
activity phase in the first 1-2 minutes of the TH reaction, levelling off to a lower stable 
activity rate after the initial phase. During the initial reaction phase, apparent Km-values 
of 29–45 μM for dioxygen were determined for all human TH isoforms, i.e. 2–40 times 
higher than previously reported for TH isolated from animal tissues. After 8 min 
incubation, the Km (O2)-values had declined to an average of 20 ± 4 μM.  
In Article 3, 22 different missense and one nonsense coding variants from patients with 
THD were produced in E. coli and subjected to biochemical studies of their enzymatic 
properties. Compared to wt-TH we observed a great heterogeneity of changes in the in 
vitro solubility, thermal stability and enzymatic activity among the mutated TH 
variants; indicating different pathogenetic mechanisms of the TH mutations found in 
patients with THD.   
In conclusion, this project has established the new oxygraphic method as a valuable 
supplement to other activity assays of AAHs, providing an assay which is versatile, 
fairly sensitive and has a high time resolution. New insights into the initial phase of the 
enzymatic reaction of the AAHs has revealed a previously undescribed shift to a low 
activity phase of the enzymes in vitro, which may be due to a rate limiting regeneration 
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of the active site iron from the inactive ferric form in the catalytic cycle. This may be 
significant in understanding the physiological effect of hypoxic conditions, as the 
concentration of oxygen in tissues reaches the Km-values for TH calculated in this 
study. Characterization of THD associated variants of mutated TH have increased the 
understanding of the molecular mechanisms of their pathogenicity; contributing to the 
understanding of the neurological symptoms and complementing the animal and 
clinical studies conducted to develop new and personalized treatments for THD 
patients.  
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1. Human tyrosine hydroxylase: Oxygen 




Tyrosine hydroxylase (TH) is a member of the enzyme family of aromatic amino acid 
hydroxylases (AAH). The first AAH to be isolated was phenylalanine hydroxylase 
(PAH) in 1957; its function had already been demonstrated by transformation of 
labelled phenylalanine to tyrosine in water-soluble liver extracts (Kaufman, 1958). In 
1964, the first reports of TH activity in neural tissues were published (Kaufman, 1964; 
Nagatsu et al., 1964c) and shortly thereafter tryptophan hydroxylase (TPH) (Grahame-
Smith, 1964; Lovenberg et al., 1967). The requirement of PAH for a tetrahydropterin 
cofactor was shown using the synthetic cofactor analogues 6,7-
dimethyltetrahydropterin and 6-methyltetrahydropterin (Kaufman and Levenberg, 
1959). In 1963, the natural cofactor was identified as tetrahydrobiopterin (BH4), as this 
compound was isolated from rat liver extracts (Kaufman, 1963).      
1.1.1 General introduction to the aromatic amino acid hydroxylases (AAHs) 
 The AAHs tyrosine hydroxylase (TH; MIM #191290), phenylalanine hydroxylase 
(PAH; MIM #612349) and tryptophan hydroxylase 1 and 2 (TPH1; MIM #191060, 
TPH2; MIM #607478), are considered to be homologous enzymes in structure and 
function. A common ancestry for the enzymes in this family have been proposed 
(Ledley et al., 1987; Siltberg-Liberles et al., 2008), as they have approximately 60 % 
DNA sequence identity and 85 % amino acid sequence identity in their catalytic 
domains.  
All AAH contain a single atom of non-heme iron per enzyme subunit; they require BH4 
as cofactor and use molecular oxygen to hydroxylate their amino acid substrates. The 
reaction stoichiometry has been found to be 1:1 for all substrates and products formed 
(Fig. 1). The active site iron is coordinated by two histidine residues and one glutamate 
as ligands to the iron in all three hydroxylases, and the iron has to be in the ferrous (II) 
redox state for the enzyme to be active (Costas et al., 2004; Flatmark and Stevens, 
1999; Teigen et al., 2007).  
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Aromatic amino acid + tetrahydropteridine + O2  hydroxylated amino acid + 
dihydropteridine + H2O 
 Fig. 1. General reaction of the aromatic amino acid hydroxylases  
 
The normal reaction stoichiometry is dependent on optimal positioning of the 
substrates in the active site of the enzyme. Using alternative substrates or changing the 
geometry of the active site can alter the stoichiometry and cause a partially or fully 
“uncoupled” reaction to take place. In an “uncoupled” reaction more substrate is 
consumed than product formed (Kappock and Caradonna, 1996). In reactions where 
more oxygen is consumed than product formed, the excess oxygen may be released as 
reactive oxygen species (ROS). ROS in vivo are potentially harmful to cells.  
 
1.1.2 Structure of the aromatic amino acid hydroxylases 
The AAHs fold in similar tertiary structures, with an amino-terminal regulatory domain 
(100-160 amino acid residues), a catalytic domain (approx. 300 residues) and a 
tetramerization domain at the carboxyl terminus (approx. 40 residues). All four 
enzymes form homotetramers in solution. The regulatory domains differ between the 
AAHs, with only 15 % sequence identity (Daubner et al., 1997), and are also the 
domains that interact with kinases, phosphatases and binding proteins, like 14-3-3 and 
α-synuclein (Alerte et al., 2008; Khan et al., 2012; Kleppe et al., 2014; Lou et al., 2010; 
Skjevik et al., 2014). The common part of the regulatory domains contains an ACT 
fold that can serve as a sensor modulating allosteric responses to amino acids (Arturo 
et al., 2016; Kobe et al., 1997).  All of the residues required for activity and substrate 
binding are located within the catalytic domain (Daubner et al., 1993; Moran et al., 
1998). Crystal structures are available of the catalytic domains of human (pdb file 
1PAH) (Erlandsen et al., 1997) and rat (pdb file 2PHM) (Kobe et al., 1997) PAH; rat 
(pdb file 1TOH) (Goodwill et al., 1997) and human (pdb file 2XSN) (Muniz et al. 2010) 
TH; human (pdb file 1MLW) (Cianchetta et al., 2010; Wang et al., 2002) and chicken 
(pdb file 3E2T) (Windahl et al., 2008) TPH 1, and human TPH 2 (pdb file 4V06) 
(Kopec et al. 2014) establishing their common structure. Recently, a structure of full-
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length tetrameric rat PAH in its inactivated form was published (pdb file 5DEN) 
(Arturo et al., 2016). 
For PAH, a crystal structure with both BH4 and an amino acid bound to the catalytic 
domain has been produced (Andersen et al., 2003), and while there is no available 
structure of either TPH or TH with both BH4 and an amino acid substrate bound 
together, there are separate structures of chicken TPH with tryptophan bound and 
human TPH with dihydrobiopterin bound (Wang et al., 2002; Windahl et al., 2008). 
These structures make it possible to describe the interactions of all AAH with 
substrates. BH4 interacts with the side chains of a glutamate and a phenylalanine 
residue; the remaining interactions are with backbone atoms. The carboxylate of the 
amino acid substrate interacts with an arginine and an aspartate residue. The side chain 
of the amino acid substrate is held in a hydrophobic pocket made up of a proline, a 
histidine that is also a metal ligand, a phenylalanine, and either a phenylalanine in TPH 
or a tryptophan in TH and PAH (Almas et al., 2000; Andersen et al., 2001; Andersen 






































Fig. 2. Structure of the AAHs. 
 
A. Detail of hTH active site with bound Zn2+ (PDB 2XSN) and selected residues  
B. Schematic illustration of the domain organization of the AAHs; the                 
regulatory N-terminal domain (red) containing one or more serine            
phosphorylation sites, catalytic domain (blue), and oligomerization domain 
(green).  
C. Ribbon diagrams of the catalytic and tetramerization domains of human tyrosine 
hydroxylase (upper left, PDB 2XSN), phenylalanine hydroxylase (upper right, 
4ANP), tryptophan hydroxylase 1 (lower left, 1MLW) and tryptophan hydroxylase 




1.1.3 Reaction mechanisms of aromatic amino acid hydroxylases with 
emphasis on tyrosine hydroxylase  
Based on steady-state kinetic studies of the recombinant rat TH catalyzed reaction, a 
sequential reaction mechanism has been proposed, with an ordered binding of 
tetrahydrobiopterin (BH4), dioxygen and finally tyrosine (Tyr) (Fitzpatrick, 1991). The 
binding of BH4 to TH results in the closing of a loop over the active site; possibly 
converting the amino acid binding site to the active form (Sura et al., 2006). All  studies 
of the hydroxylases are consistent with a common reaction mechanism (Fitzpatrick, 
2003); first the reaction of the BH4, oxygen and the active site iron to form the reactive 
hydroxylating intermediate and then the insertion of the oxygen into the amino acid. 
The partial reactions are tightly coupled. Without the tetrahydropterin and the amino 
acid bound, the enzyme will not react productively with the oxygen and instead the 
iron is oxidized to the ferric inactive form (Chow et al., 2009; Frantom et al., 2006). 
The catalytic activity of TH requires the binding of tyrosine, BH4 and molecular oxygen 
to the catalytic site that harbors the ferrous iron coordinated by the side chains of two 
histidines and a glutamate (Fig. 2 A.). Studies of the enzyme by both X-ray 
crystallography and spectroscopic techniques have shown that the tyrosine and BH4 do 
not bind directly to the iron; rather, binding of tyrosine and BH4 leads to structural 
changes that result in the metal center transitioning from 6- to 5- coordinate (Chow et 
al., 2009). These changes in the catalytic site increase the oxygen reactivity with the 
iron > 100-fold, and thus trigger the start of a two-step reaction mechanism (Chow et 





Fig. 3 Reaction of tyrosine hydroxylase 
The first step of the TH reaction is the hydroxylation of the 4a-carbon to yield 4a-
hydroxy(tetrahydro)pterin. In this step, the BH4 donates two electrons for the heterolytic 
cleavage of the O-O bond and leaves a Fe(IV)-oxo intermediate. The Fe(IV)-oxo species have 
been trapped for TH and characterized by Mössbauer spectroscopy (Eser et al., 2007). The 
second step of the catalytic mechanism involves attack of the Fe(IV)-oxo species on the phenol 
side chain of tyrosine to produce L-DOPA by electrophilic aromatic substitution (Eser et al., 
2007; Frantom et al., 2006; Hillas and Fitzpatrick, 1996). Tyrosine hydroxylase is a 
stereospecific enzyme for both substrate and cofactor (Bailey and Ayling, 1978). Partial 
uncoupling of the enzyme reaction has been observed with several amino acid and cofactor 
analogues. 
 
1.1.4 Physiological aspects of the aromatic amino acid hydroxylases 
PAH is mainly expressed in the liver and kidney, but minor amounts are also found in 
in melanocytes (Schallreuter et al., 2004), where epidermal PAH produces L-Tyr from 
the essential amino acid L-Phe, supporting melanogenesis. In liver, the hydroxylation 
of L-Phe to L-Tyr is the first and rate-limiting step in the catabolism of phenylalanine, 
resulting in the formation of one molecule of fumarate and one of acetoacetate (Acetyl-
CoA). PAH activity is highly regulated to prevent depletion of L-Phe, which is an 
essential amino acid required for protein synthesis, but also to prevent the excess of 
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this neurotoxic amino acid. Dysfunction in PAH leading to hyperphenylalaninemia and 
PKU is described in further detail below.  
In rats, 20-45 % of the liver PAH is believed to be in an inactive state (Shiman et al., 
1982), and the authors of that study made the point that there is enough PAH present 
in the liver to deplete the serum of phenylalanine in a few minutes if all PAH was to 
become fully activated. The PAH activity is regulated by different mechanisms, and 
physiologically glucagon is known to indirectly stimulate the formation of tyrosine by 
PAH. PAH is allosterically activated by its substrate phenylalanine, which binds with 
positive cooperativity to the enzyme. The mechanism of activation is not fully 
understood, and there are conflicting opinions concerning the site of cooperative 
binding of L-Phe (Fitzpatrick, 2012; Flydal and Martinez, 2013). There is evidence for 
L-Phe binding to a specific site in the regulatory domain of PAH, the ACT domain, 
causing a conformational change and dimerization of the domains (Gjetting et al., 
2001; Jaffe et al., 2013; Zhang and Fitzpatrick, 2016), but other studies have found that 
phenylalanine causes the conformational change and subsequent activation of PAH 
upon binding to the catalytic site through a homotropic interaction between different 
subunits (Martinez et al., 1990; Martinez et al., 1993; Thorolfsson et al., 2002; 
Thorolfsson et al., 2003). On the other hand, the natural cofactor BH4 negatively 
regulates PAH activity besides being essential in catalysis. Furthermore, 
phosphorylation of PAH at Ser16 increases the activity of PAH by reducing the Kd for 
L-Phe activation (Doskeland et al., 1996).  
TH is the rate-limiting enzyme in the synthesis of dopamine, adrenaline and 
noradrenaline, i.e. the catecholamine neurotransmitters. TH is mainly expressed in the 
dopaminergic neurons of the ventral tegmental area and substantia nigra pars 
compacta, in the noradrenergic neurons of the locus coeruleus, and in sympathetic 
neurons and in the adrenal medulla (Nagatsu and Ichinose, 1991). 
 22
 In humans, a single TH gene encodes four main isoforms of TH protein (hTH), 
generated by alternative splicing of pre-mRNA (Grima et al., 1987). There is no 














Fig. 4. Alternative splicing of mRNA results from the use of two donor sites in exon 1 and 
inclusion/exclusion of exon 2 in human TH (hTH). Isoform 1 (hTH1) has no insertion and 
isoform 4 (hTH4) has the longest insertion of 31 additional amino acid residues.  
TH activity is highly regulated, as the catecholamines are essential in a variety of 
physiological functions. Excess catechol formation is toxic to cells and can lead to 
protein and DNA damage via oxidation of catecholamines, producing reactive 
quinones and oxygen radicals (Hastings and Zigmond, 1994; Stokes et al., 1996). 
Accordingly, TH activity is subject to negative feedback inhibition by catecholamines. 
The catecholamines coordinate to the ferric iron, leaving TH inactive and preventing 
the binding of the cofactor BH4. Human TH (hTH) is phosphorylated by a variety of 
protein kinases at four Ser/Thr residues (in positions 8, 19, 31 and 40 in hTH1) in the 
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N-terminal regulatory domain (Andersson et al., 1988; Haycock, 1990; Haycock and 
Haycock, 1991; Kumer and Vrana, 1996), and phosphorylation of Ser40 by cAMP-
dependent protein kinase (PKA) results in a decrease in the Km for the cofactor BH4 as 
well as a reduced affinity for the catecholamine feed-back inhibitors (Le Bourdelles et 
al., 1991). The detailed molecular mechanisms underlying the catecholamine inhibition 
are yet to be explicated. However, it has been suggested that there are several different 
binding modes for the catecholamine inhibition, i.e. first, a high affinity binding of 
catecholamine to the active site iron causing an irreversible inhibition (Andersson et 
al., 1988). This produces a significant reduction of the maximum reaction velocity 
(Vmax) and disruption of the binding of the cofactor BH4 (Briggs et al., 2011; Gordon 
et al., 2008). The high affinity catecholamine binding requires the regulatory domain 
of TH to be present (Gordon et al., 2009b). This form of catecholamine inhibition can 
only be relieved by phosphorylation of the serine 40 residue in the regulatory domain, 
producing a conformational change that allows the catecholamine to dissociate (Almas 
et al., 1992). A change in TH structure becoming more compact upon binding of 
catecholamines and more open upon phosphorylation of serine 40 has been 
demonstrated (Bevilaqua et al., 2001); and is believed to reflect an interaction between 
the regulatory and catalytic domains. Second, a low affinity binding of catecholamines 
to TH, producing a reversible inhibition competitive to binding of the cofactor BH4, 
but which does not decrease the maximal reaction velocity has been described (Gordon 
et al., 2008). High and low affinity binding of catecholamines can occur 
simultaneously, but studies of the interaction between catecholamines and catalytic site 
residues suggest overlapping sites of high and low affinity binding (Briggs et al., 2011; 
Gordon et al., 2008). A model of catecholamine binding considering that the size of the 
active site is not sufficient to bind both catecholamines has been suggested; and a 
detailed study of the TH dimer has shown that the dimer is probably the core regulatory 
unit of TH, displaying both high and low affinity catecholamine inhibition, with 
characteristics indistinguishable from the tetramer, except for cooperativity in 
catecholamine binding, as expected (Briggs et al., 2014).  
TPH 1 and 2 are rate-limiting in the synthesis of the neurotransmitter serotonin and the 
neurohormone melatonin. There are two isoforms of human TPH encoded by two 
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different genes, TPH1 and TPH2 (Walther and Bader, 2003). The chromosomal 
locations of the genes differ; TPH1 is located on chromosome 11, while TPH2 is on 
chromosome 12. The nucleotide sequences of the two human enzymes are 70% 
identical, mainly differing in the regulatory domain. The regulatory domain of TPH 1 
contains approximately 88 residues, while TPH 2 contains an additional 46 residues. 
TPH 1 was the first discovered, and is the most studied enzyme form. TPH 1 is mainly 
expressed in peripheral tissue, in the enterochromaffin cells in the gut, spleen, thymus, 
skin and retina; and also in the pineal gland (Cote et al., 2003; Hornung, 2003; 
Slominski et al., 2003), while TPH 2 is considered to be neuron-specific and expressed 
in the serotonergic neurons of the raphe nuclei and the myenteric neurons in the gut 
(Liang et al., 2004; Zill et al., 2004). In the central nervous system (CNS), serotonin 
acts as a neurotransmitter where it binds to 5-HT receptors; in the pineal gland, it also 
serves as a precursor for melatonin biosynthesis. In the periphery, serotonin constricts 
large blood vessels and regulates platelet adhesion; in the intestinal system, serotonin 
initiates peristaltic and secretory reflexes (Cote et al., 2003; Mawe and Hoffman, 2013; 
Slominski et al., 2003). TPH activity shows diurnal variation (Liang et al., 2004; Malek 
et al., 2004). Like the other AAH TPH is subject to regulation by phosphorylation on 
serine residues in the N-terminal domain. 
1.1.5 Enzyme activity essays  
The activity of TH has been studied using different assay methods. In 1964, the first 
report of conversion of L-Tyr to L-DOPA in cell-free preparations of tissue 
homogenates was published (Nagatsu et al., 1964a). A radiochemical assay using 14C-
L-Tyr as a substrate in the conversion reaction, absorbing the resulting catechols on an 
alumina column was applied to demonstrate a tyrosine hydroxylase activity in the 
tissue homogenates. Later, an activity assay where 3H-L-Tyr replaced the 14C-L-Tyr as 
a substrate, measuring the release of tritiated water or the 3H-L-DOPA formed in the 
catalytic reaction, was developed. This method was argued to be a simpler and less 
laborious method of activity measurement, as it left the isolation of catecholamines 
unnecessary (Nagatsu et al., 1964b). Variations of the radiochemical assay also include 
a method based on the enzymatic decarboxylation of 14C-labelled L-DOPA and 
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measuring the released 14CO2, an assay proposed to be more sensitive than previously 
described methods (Waymire et al., 1971).  
Further interest in developing methods to study TH activity, making labelled substrates 
and scintillation spectrometers obsolete, resulted in the fluorometric assays (Nagatsu 
and Yamamoto, 1968; Yamauchi and Fujisawa, 1978). L-DOPA formed in the TH 
reaction was subjected to the trihydroxyindole derivatization method and the highly 
fluorescent L-DOPA derivative was isolated from the reaction mixture on columns 
before fluorometric detection. This method was found to yield comparable results to 
the radiochemical methods, and used to measure activity in tissues such as brain or 
adrenal glands accurately, although being less sensitive than the radioassays.    
Shiman et al. applied several assay methods to study TH activity in bovine adrenal 
medulla (Shiman et al., 1971). Comparing to the previously described radiochemical 
and fluorometric assays, they also presented a colorimetric assay method, taking 
advantage of L-DOPA’s ability to react with nitrous acid in the presence of sodium 
molybdate to produce a compound that absorbs light with a maximum at 510 nm. They 
also provide the first description of an oxymetric assay, employing a Gilson oxygen 
electrode to measure the consumption of oxygen in the TH reaction. Additionally, they 
measured the substrate dependent oxidation of cofactor by a direct method, recording 
the increasing absorbance of tetrahydropterins, and indirectly by measuring the 
absorbance of NADH oxidized in the regeneration of the tetrahydropterins used in the 
catalytic reaction. All assay methods in their study were compared, and the authors 
argued that with suitable precautions, both high accuracy and high precision can be 
obtained. However, these methods have been assessed by others to lack the sufficient 
sensitivity to be generally useful (Blank and Pike, 1976). 
During 1970-1980, new assay methods applying high performance liquid 
chromatography (HPLC) were developed (Blank and Pike, 1976). By passing tissue 
homogenates and other reaction mixtures through a HPLC column, separation of 
components in the reaction mixture may be achieved, and L-DOPA formed in the TH 
reaction can be quantified by electrochemical (Blank and Pike, 1976; Naoi et al., 1988; 
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Philipp, 1987) and fluorometric detection (Bailey and Ayling, 1980; Bailey et al., 1989; 
Haavik and Flatmark, 1980). Common advantages for the HPLC based assay methods 
are their high sensitivity, reliability and precision, less expensive reagents, and being 
less laborious and time consuming compared to radiochemical methods.  
 Detection method Sensitivity -








Scintillation counting of     
 14C-L-DOPA ~ 5 pmol n.s. (Nagatsu et al., 1964a) 
 14CO2  5 pmol n.s. (Waymire et al., 1971) 
 3H-L-DOPA ~ 5 pmol n.s. (Nagatsu et al., 1964c) 




Direct measurement of 
   
 L-DOPA  100 pmol         2 (Nagatsu and Yamamoto, 
1968; Nagatsu et al., 1979b) 
 L-DOPA  100 pmol n.s. (Yamauchi and Fujisawa, 1978) 




n.s. n.s. (Shiman et al., 1971) 
Oxygraphic 
assay 
Direct measurement of 
oxygen consumption  
   
 Gilson electrode n.s. n.s. (Shiman et al., 1971) 
     
HPLC based 
assay 
    
 Electrochemical- 
voltametric 
0,2 pmol 3 (Blank and Pike, 1976) 
 Electrochemical-
voltametric 
2 pmol 3 (Philipp, 1987) 
 Electrochemical-
voltametric 
5 pmol  (Nagatsu et al., 1979a) 
 Electrochemical-
coulometric 
0,25 pmol 5 (Naoi et al., 1988) 
     
 Fluorometric 5 pmol 3 (Haavik and Flatmark, 1980) 
 Fluorometric 1 pmol 2 (Bailey et al., 1989) 
 
Table 1. Summary of the assay methods developed for the tyrosine hydroxylase reaction. 
Sensitivity is reported according to the original articles published. N.s.= not specified  
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1.1.6 Regulation of AAH activity with emphasis on their phosphorylation 
and interaction with 14-3-3 proteins  
Phosphorylation of serine residues in the regulatory amino-terminal domain is a 
common mode of short-term regulation of the AAHs (Daubner et al., 2011). All four 
AAHs are phosphorylated by cAMP-dependent protein kinase (PKA) and Ca2+ 
/calmodulin dependent protein kinase (CaMKII) (Fitzpatrick, 2000; Winge et al., 
2008); upon phosphorylation the enzymes are activated and/or stabilized; and 
phosphorylation of TH and TPH facilitates binding of 14-3-3 proteins (Ichimura et al., 
1987; Kleppe et al., 2001). Other protein kinases can phosphorylate AAHs; however, 
only PKA and CaMKII are mentioned here as they are the most studied kinases 
involved in the regulation of the AAHs. 
Phosphorylation of PAH at Ser16 increases the basal activity of PAH; a localized 
conformational change in the structure of the enzyme leading to a more “open” active 
site (Miranda et al., 2002; Miranda et al., 2004), thus less phenylalanine is required to 
activate the hydroxylation reaction (Doskeland et al., 1996). In addition, 
phosphorylation seems to decrease the rate of proteolysis of PAH (Miranda et al., 
2004).  
TPH 1 is phosphorylated on Ser58 by PKA (Johansen et al., 1996; Vrana et al., 1994) 
leading to activation of the enzyme; while TPH 2 phosphorylation occurs on Ser19 by 
CaMKII and PKA (Kuhn et al., 2007; Winge et al., 2008) and on Ser104 by PKA, 
corresponding to Ser58 in TPH 1 (Winge et al., 2008). 
Compared to PAH and TPH 1 and 2; phosphorylation and interaction with 14-3-3 
proteins for TH have been extensively studied. TH can be phosphorylated on four 
serine residues; Ser8 (Thr8 in some species, including human TH), Ser19, Ser31 and 
Ser40. Several kinases are involved in phosphorylating TH, and show specificity in the 
serine residue they phosphorylate (Dunkley et al., 2004). Increased TH activity is seen 
primary upon phosphorylation on Ser40; which both increases the affinity for the 
cofactor BH4 and contributes to alleviate the catecholamine feedback inhibition (Almas 
et al., 1992; Daubner et al., 1992; Haavik et al., 1990; Le Bourdelles et al., 1991). On 
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the other hand, phospho-Ser40 TH is more susceptible to thermal denaturation in vitro, 
possibly reflecting a conformational change, leading to a more unstable enzyme (Gahn 
and Roskoski, 1995; Lazar et al., 1981; Ramsey and Fitzpatrick, 2000).  
Phosphorylation of Ser31 also activates TH by increasing the affinity of TH for BH4 
(Halloran and Vulliet, 1994; Haycock et al., 1992; Sutherland et al., 1993). However, 
no evidence for relieving of the catecholamine inhibition upon Ser31 phosphorylation 
was found (Haycock et al., 1992; Salvatore et al., 2001; Wu et al., 1992). In situ studies 
indicate that Ser31 phosphorylation occurs later than Ser40 and Ser19 phosphorylation 
in response to depolarization stimuli (Thomas et al., 1997; Waymire et al., 1988). 
Evidence for differences in phosphorylation on Ser31 between the different isoforms 
of hTH has been found, where the Ser35 in hTH2 (corresponding to Ser31 in hTH1) 
was not phosphorylated in response to stimuli in a cell culture when the same 
conditions lead to phosphorylation of Ser31 in hTH1. Further, the phosphorylation of 
Ser31-hTH1 increased the phosphorylation of Ser40, an effect that was absent in the 
hTH2 (Gordon et al., 2009a). Compartmental differences of TH phosphorylated on 
Ser31 was shown in a study comparing TH phosphorylation in rat striatum, substantia 
nigra, ventral tegmental area and nucleus accumbens (Salvatore and Pruett, 2012).  
These findings propose a difference in regulation between the TH isoforms.  
Phosphorylation of Ser19 in TH does not activate the enzyme directly either in vitro or 
in situ (Sutherland et al., 1993; Toska et al., 2002). There are, however, evidence for 
important regulatory consequences for phosphorylation of this residue in TH. First, a 
hierarchical regulation of phosphorylation of TH has been suggested, where Ser19 
phosphorylation leads to a conformational change in TH increasing the access to 
phosphorylation of Ser40 (Bevilaqua et al., 2001; Toska et al., 2002). Second, 
phosphorylation of Ser19 is essential in interaction of TH with stabilizing/activating 
proteins, e.g. 14-3-3 proteins, as discussed below. 
No evidence for an effect on TH activity or catecholamine production have been found 
for phosphorylation of TH Ser/Thr8 (Dunkley et al., 2004). 
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The 14-3-3 proteins are regulatory molecules present in all eukaryotic species, in 
mammals 7 different genes codes for different isoforms. The 14-3-3 isoforms β, γ, ε, 
η, τ and ζ are expressed abundantly in brain, and are shown to regulate TH and TPH 
activity (Ichimura et al., 1988).While all four AAHs have similar ACT regulatory 
domains, TH and TPH 2 have a long N-terminal extension (residues 1-43 in hTH1) that 
contain the Ser19 residue facilitating interaction with 14-3-3 proteins (Murphy et al., 
2008; Skjevik et al., 2014; Winge et al., 2007).  Phosphorylation of TH Ser19 is shown 
to initiate binding of 14-3-3 proteins (Daubner et al., 2011; Halskau et al., 2009; Kleppe 
et al., 2014), and there is also evidence for binding to 14-3-3 proteins for phospho-
Ser40-TH and double phosphorylated Ser19-Ser40-TH (Hritz et al., 2014; Kleppe et 
al., 2001). The 14-3-3 proteins can be both monomers and dimers, and form homo- or 
heterodimers. In dopaminergic cells, phospho-Ser19-TH interacts with multiple 14-3-
3 dimer isoforms, resulting in activation of TH and inhibition of its dephosphorylation 
(Ghorbani et al., 2016). Structural studies of the N-terminal peptide (1-43) of TH 
reveals a conformational change upon binding of 14-3-3γ by phospho-TH-Ser19; 
giving a more extended structure compared to non-phosphorylated TH (Skjevik et al., 
2014).  
 
1.2 AAHs in human disease 
 
1.2.1 Phenylketonuria as a model disease for studying the effects of 
mutations in aromatic amino acid hydroxylases 
Classical phenylketonuria (PKU), or Følling’s disease, is an inborn defect in the ability 
to metabolize the amino acid phenylalanine (Scriver, 2007; van Spronsen, 2010), 
causing increased levels of phenylalanine in the blood. The disease was discovered in 
1934, when dr. Følling found phenylpyruvic acid in the urine of a pair of siblings with 
mental retardation (Følling, 1934). PKU can be categorized by severity based on the 
phenylalanine levels at diagnosis and dietary tolerance to phenylalanine; classical PKU 
(blood levels of L-Phe >1200 μmol/L), mild PKU (600–1200 μmol/L)  and mild 
hyperphenylalaninemia (120–600 μmol Phe/L) (Blau et al., 2010). Atypical PKU can 
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also occur due to congenital deficiency of BH4 synthesis (Shintaku, 2002). The 
symptoms of PKU can vary from mild to severe, and without treatment the child can 
develop intellectual disability, and in severe cases seizures, delayed development, 
behavioral problems and psychiatric disorders like depression and anxiety (Brumm et 
al., 2010; Pey et al., 2007; Scriver, 2007). In Norway an average of 3-5 children are 
born with this genetic defect every year. Since 1978, the Norwegian national post-natal 
screening program has included screening for PKU. With early treatment with a 
phenylalanine restricted diet and supplementation with essential amino acids, 
development of disability can be avoided (Bickel et al., 1953; Enns et al., 2010; Smith 
and Knowles, 2000).   
To date, more than 950 different mutations in PAH are reported 
(www.biopku.org/pah, accessed March 2016). The majority of the mutations are 
missense mutations (approx. 60 %), the remaining mutations are small deletions (13 
%), splice mutations (11%), putative silent mutations (7 %), stop/nonsense mutations 
(5 %), small insertions (1 %), and large deletions (up to 3%) (Kozak et al., 2006; Scriver 
et al., 2003). In extensive population studies associating genotype with biochemical 
phenotype in the patients (Desviat et al., 1997; Eisensmith and Woo, 1995; Guldberg 
et al., 1998) and in which the severity of most mutations can be predicted, there are 
notable inconsistencies for a few missense mutations, in the sense that they are 
associated with variable phenotypes in patients with identical genotypes.  Several of 
the mutated variants of PAH found in PKU patients have been characterized in vitro, 
and the activity, kinetic properties and stability of mutated enzyme have been studied. 
The main molecular mechanism of enzyme dysfunction is considered to be instability 
and misfolding of the enzyme, leading to degradation and/or aggregation of the protein 
(Gersting et al., 2008; Pey et al., 2007; Wettstein et al., 2015).  
 
The mechanisms of the cognitive impairment in PKU are not fully solved, but a current 
hypothesis involves the role of hyperphenylalaninemia on the function of the other 
aromatic amino acid hydroxylases, TH and TPH1/TPH2. Furthermore, an affection of 
protein synthesis in the brain has been reported, leading among other to dysfunction in 
myelin formation by glia cells (oligodendrocytes) (de Groot et al., 2010). Recently, an 
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amyloidosis-like pathophysiology has also been suggested for PKU, based on evidence 
for formation of neurotoxic fibrils of phenylalanine (Adler-Abramovich et al., 2012). 
The transport of large neutral amino acids (LNAA) (phenylalanine, tyrosine, 
tryptophan, leucine, isoleucine, valine, histidine, methionine and threonine) across the 
blood-brain barrier is mainly carried out by the LAT-1-transporter. The LAT-1 
transporter binds the LNAA with different affinities, and is also a counter-transporter, 
e.g. for each LNAA transported into the brain, another is transported out (Zielke et al., 
2002). This is a competitive process, and hyperphenylalaninemia leads to a higher 
transport of phenylalanine into the brain, reducing transport of the other LNAAs as a 
consequence (van Spronsen et al., 2010). L-Phe is also a competitive substrate for TH 
(Fukami et al., 1990). Low concentrations of tyrosine and tryptophan in the brain, the 
substrates of the rate-limiting steps in the production of the neurotransmitters 
dopamine, noradrenaline and serotonin, respectively, can lead to dysfunction in 
neuronal signaling (de Groot et al., 2010). The protein production in the brain is also 
compromised, with potentially extensive consequences (de Groot et al., 2010; Moller 
et al., 1998; Weglage et al., 1998). 
 
1.2.2 Tyrosine hydroxylase deficiency 
Congenital tyrosine hydroxylase deficiency (THD) is found in DOPA responsive 
dystonia and some related neurological syndromes with predominantly motor 
symptoms. The clinical manifestations of THD are variable, with different levels of 
severity, age of onset and symptom profiles. THD patients are clinically categorized as 
type A or B; type A representing the group of patients with mild parkinsonian 
symptoms and type B, those with a more severe early onset lethal disease. THD appears 
to have an exclusively autosomal recessive inheritance. The approx. 70 patients who 
have been described so far are either homozygous or compound heterozygous for 
mutations in the exons or the promoter region of TH gene. From 1995-2012, ~ 50 
different disease related missense mutations and 4 nonsense mutations in the TH gene 
have been reported. Additionally, 3 mutations in the promoter region of the TH gene 
have been found in THD (Willemsen et al., 2010).  
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Recently, two different knock-in mouse models of tyrosine hydroxylase deficiency 
have been studied (Korner et al., 2015; Rose et al., 2015). The mouse models carry the 
R203H and Q382K mouse Th mutations, respectively, corresponding to the human 
TH4 R233H and Q412K mutations. Both knock-in mice homozygous for mutations 
displayed dystonic movements with diurnal fluctuations and hypokinesia; the Q382K 
knock-in mice had significant improvement in the symptoms upon L-DOPA or 
trihexyphenidyl supplementation, while the R203H mice did not respond to supplement 
treatment. The mice seem to represent good models for each of the sub- types of THD; 
the first carrying the R203H mutation displaying features of the type B THD and the 
second, Q382K, of type A, in accordance with the phenotype association of each 
mutation in human THD (Willemsen et al., 2010).   
 
1.2.3 Parkinson’s disease/syndrome  
Parkinson disease (PD) is a chronic and progressive neurological disease associated 
with a loss of dopaminergic neurons. In most cases the disease is sporadic, but 
genetically inherited cases also exist (Ross and Farrer, 2005). One of the major 
pathological features of PD is the presence of protein aggregates that localize in 
neuronal cytoplasm as Lewy bodies, mainly composed of α-synuclein (α-syn) and 
ubiquitin. Immunohistochemical studies of the Lewy bodies of PD in post mortem 
brains have also provided evidence for catechol and TH inclusions (Goldstein et al., 
2011). The selective degeneration of dopaminergic neurons suggests that dopamine 
itself may contribute to the neurodegenerative process in PD. Degenerating neurons in 
the substantia nigra down-regulate the expression of dopamine transporter and TH; a 
paradox in the dopamine depleted neuron that is not fully understood (Obeso et al., 
2008). In the TH reaction, reactive oxygen species can be formed if the geometry of 
the active site is altered or alternative substrates are available (Haavik and Toska, 
1998). Reactive oxygen species can damage proteins and DNA, leading to cell damage 
(Perfeito et al., 2012). L-DOPA has been shown to be a substrate for TH, with 
comparable Vmax and Km values as for tyrosine (Haavik, 1997). Oxidation of L-DOPA 
by TH is thought to mediate formation of neuromelanin and possibly to be involved in 
 33 
the L-DOPA toxicity. Thus, a direct pathogenic role of TH in the neurodegenerative 
process of PD has been suggested (Haavik and Toska, 1998). 
 
1.2.4 A possible role of TH in hypoxia induced disease  
At higher altitudes the barometric pressure decreases, leading to lower oxygen 
concentration in the air. Before acclimatization occurs, hypoxia causes activation of 
the sympathetic nervous system and thereby increased respiration, blood pressure and 
heart rate. Altitude sickness is a pathological effect of high altitude in humans, 
presenting with unspecific symptoms such as headaches, nausea, fatigue, dizziness and 
sleep disturbances (Joseph and Pequignot, 2009). Acute altitude sickness can progress 
to high altitude cerebral edema or pulmonary edema which is fatal; however, in most 
cases the acclimatization process relieves the symptoms (Joseph and Pequignot, 2009; 
Wilson et al., 2009). Studies in humans have shown a temporary reduction in 
catecholamine synthesis during hypoxia (Leuenberger et al., 1991; Sevre et al., 2001). 
It has also been demonstrated that the concentration of plasma catecholamines 
correlates well with the peripheral oxygen saturation in a study of participants of a 
climbing expedition (Rostrup, 1998). Additionally, there have been several reports of 
normobaric hypoxia reducing the in vivo tyrosine hydroxylation in rat brain (Brown et 
al., 1974; Davis and Carlsson, 1973; Davis, 1975). Reduced brain noradrenaline after 
hypoxia has also been found (Hayashi et al., 1990). Reported TH Km-values for O2 vary 
from 3-24 μM (Fisher and Kaufman, 1972; Fitzpatrick, 1991; Ikeda et al., 1966; Katz, 
1980; Numata et al., 1977). Although the O2 concentration in brain, kidney and liver 
tissue of living animals is uncertain (Feinsilver et al., 1987; Rolett et al., 2000), it is 
likely that at sea level the tissue partial pressures of oxygen may get close to the Km-
levels suggested for rat TH and be rate limiting. Thus, at high altitude, the partial 
oxygen tension in peripheral tissue of humans most probably will reach levels in the 
range of the Km-values of rat TH, especially in subjects not fully acclimatized.  
 
Chronic intermittent hypoxia, as seen in obstructive or central sleep apnea syndrome 
(OSAS, CSAS), is associated with hypertension, metabolic abnormalities such as 
hyperglycemia and hypercholesterolemia and increased risk of cardiovascular disease 
(Passali et al., 2015; Toraldo et al., 2015). Hypoxia is sensed by the carotid bodies 
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which evokes increased sympathetic nerve activity (Prabhakar et al., 2015), and 
increased activity of the adrenal medulla catecholamine production has been 
demonstrated (Peng et al., 2014). A role of TH in sleep apnea syndrome has been 
suggested, and studies of intermittent hypoxia (IH) on PC12 cells have demonstrated 
involvement of short term regulatory mechanisms, e.g. serine phosphorylation, of the 
TH enzyme in response to IH (Kumar et al., 2003). Hypoxia can also lead to increased 
TH gene expression via the actions of Hypoxia-inducible factor-1α, thus regulating TH 
activity in cells on a long term scale (Lim et al., 2015). 
 
1.2.5 Human tryptophan hydroxylase associated disease 
All four of the AAHs have been proposed as candidate genes in psychiatric disorders. 
For TH and PAH, the reports of association so far have been inconsistent (De Luca et 
al., 2008; Jacobsen et al., 2015; Meloni et al., 2002; Sobell et al., 1993; Wilcox et al., 
2002). Association with both TPH 1 and 2 for different psychiatric disorders like 
depression, suicidal behavior, attention deficit hyperactivity disorder (ADHD) and 
anxiety; are reported in several studies (Bach-Mizrachi et al., 2006; Boldrini et al., 
2005; Cichon et al., 2008; McKinney et al., 2008). Mutated forms of TPH2, associated 
with reduced serotonin synthesis in the brain, P449R, major depressive disorder, 
R441H, bipolar affective disorder, P209S and ADHA, R303W have been characterized 
(Winge et al., 2007). All of the variants of TPH2 show reduced solubility and thermal 
stability compared to wild-type (wt)-TPH2. The mutants R449H and R303W also have 
reduced enzymatic activity compared to wt-TPH2, in contrast to P209S and P449R that 






2.1 Protein expression, purification and mutagenesis 
For the study of THD associated variants of TH, mutations were introduced into the 
wt-hTH1 cDNA on the pET3a-hTH1 vector (Haavik et al., 1991) by PCR-based 
mutagenesis using the QuikChange mutagenesis kit (Stratagene, La Jolla, CA, USA). 
Introduction of the correct mutation and exclusion of other mutations was verified by 
Sanger sequencing of the whole coding region. Recombinant human TH, isoform 1 
(hTH1) and the mutant hTH1 were expressed in BL(21)D3pLysS  Escherichia coli 
(Invitrogen™). The bacteria were grown at 37 ̊C in LB medium containing 50 μg/ml 
of ampicillin and 34 μg/ml of chloramphenicol. The expression of T7 polymerase was 
induced at OD600 nm = 0.8 by addition of 1 mM isopropyl 6-D-thiogalactopyranoside. 
The temperature was then decreased to 25 ̊C, and the bacteria were harvested after 6 
hours incubation. The bacteria pellets were kept at -20 ̊C until purification. 
Bacteria (from 1 L of culture) were diluted in 20 mM Tris/HCl, containing 5% 
mass/vol. sucrose, 1 mM dithiothreitol (DTT), 1 mM EDTA, 0.1 mM 
phenylmethylsulfonyl fluoride and 1 tbl. Complete Protease inhibitor cocktail, EDTA-
free (Roche, Mannheim, Germany) /25 mL, and disrupted by passage through a French 
press (type FA-073 from SLM Instruments, Urbana IL) at 69 MPa. The lysate was 
centrifuged at 12 000 g for 20 min., and the supernatant was purified by heparin 
Sepharose chromatography. The purified enzymes were concentrated and stored in 
liquid nitrogen until used. 
2.2 TH enzyme activity assay  
In addition to the required substrates and cofactor for the aromatic amino acid 
hydroxylation to occur; the aromatic amino acid substrate, molecular oxygen, ferrous 
iron and a reduced pterin cofactor; the reaction mixture in our studies contains catalase 
and DTT. Catalase and DTT are beneficial for protecting the enzyme activity as 
scavenger of H2O2 and a reductant for the cofactor, respectively (Cash, 1998). The 
natural cofactor, BH4, was used in the studies presented. 
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2.3 The oxygraphic method of studying aromatic amino acid hydroxylases 
We applied the Oroboros 2K oxygraph (Oroboros Instruments, Innsbruck; and Paar, 
Graz, Austria) (Fig. 5A). This is a digital oxygraph with optimized reaction chamber 
geometry, low background noise levels, and possibilities for addition and removal of 
samples during analysis. Initial oxygen concentrations were varied by adding pure 
argon (99.996%) into the gas phase of the partially opened oxygraph chamber. The 
chamber was closed for recording of chemical oxygen consumption before the reaction 
was initiated by addition of enzyme. The oxygen flux was analyzed using the DatLab 
software (Oroboros Instruments, Innsbruck), which includes online calculation of the 












Fig. 5. Oxygraphy 
A. The Oroboros Oxygraph 2K 
B. Real time oxygraph recording of oxygen consumption of WT and mutant TH. An 
oxygraph recording of the oxygen consumption during tyrosine hydroxylation is 
represented by the blue trace, left axis. The reaction is started by hTH addition, 
indicated by an arrow. The reaction velocity vO2 (nmol min
-1 mg-1) is given by the 
red trace, right axis. After addition of 10 μg TH, the oxygen flux was measured 
directly using an oxygen electrode. 
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3 Aims of the present study 
To increase our understanding of the activity and regulation of the AAHs, as well as 
their implication in disease due to mutations that affect their function and stability. The 
work was organized in subprojects to answer specific aims 1-4:  
1. To develop improved methods of studying aromatic amino acid hydroxylases 
(AAHs), mainly focusing on their dependence of oxygen. 
2.  To investigate the role of oxygen in the AAH reactions, with an emphasis on TH.  
3. To characterize the effect of mutations in AAH, mainly PAH and TH, on their 
enzyme function and stability.  
4. Investigate the effects of missense TH mutations reported in patients with TH 











4 Summary of articles 
4.1 Article 1; An oxygraphic method for determining kinetic properties and 
catalytic mechanism of aromatic amino acid hydroxylases 
The first part of this project was focused on developing an oxygraphic method for 
determining kinetic properties and catalytic mechanism of aromatic amino acid 
hydroxylases. We applied the Oroboros Oxygraph 2k for continuously measuring the 
oxygen consumption in the hydroxylase reaction. Measurement of other substrates and 
products in the reaction was possible by removing aliquots of reaction mixture during 
the experiment and using HPLC for analysis.  
We were able to demonstrate the oxygraphic method as an uncomplicated and versatile 
tool for studying the AAHs, with fairly high sensitivity and time resolution. At a signal-
to-noise ratio of 3, we could measure enzyme activity down to ~ 1.8 nmol 
dioxygen/min/ml and recording of the oxygen concentration in the reaction mixture 
every 200 msec. Determination of kinetic properties of both wild-type and mutant 
protein and different substrates and cofactors was possible. A stable reaction 
stoichiometry of 1:1 was obtained between the amount of oxygen consumed and the 
tyrosine formation when the natural cofactor (6R)-tetrahydrobiopterin was added as 
electron donor in the phenylalanine hydroxylase (PAH) reaction. In comparison, low 
and variable coupling efficiency values between oxygen consumption and tyrosine 
formation were found using the parent unsubstituted tetrahydropterin. Furthermore, we 
studied the phenylketonuria-associated PAH mutant R158Q and found that the reaction 
had a coupling efficiency of about 80 % compared to the wild-type enzyme under 
similar conditions. In this reaction the amount of H2O2 produced in the reaction 
catalyzed by R158Q PAH was about four times higher than the amount produced by 






4.2 Article 2; Oxygen dependence of tyrosine hydroxylase 
In this part of the project we focused on the effects of oxygen concentration on the TH 
reaction. The effect of dioxygen on TH activity was studied, measuring the formation 
of DOPA from tyrosine, 3H2O from 3,5-3H-tyrosine, or by direct oxygraphic 
determination of oxygen consumption. During the initial 1–2 min of the reactions, we 
observed a phase of high enzyme activity, followed by a decline in activity. Apparent 
Km-values of 29–45 μM for dioxygen were determined for all human TH isoforms in 
the initial high activity phase, i.e. 2–40 times higher than previously reported for TH 
isolated from animal tissues. After 8 min incubation, the Km (O2)-values had declined 
to an average of 20 ± 4 μM. The lower activity phase is possibly related to a turnover 
dependent substoichiometric oxidation of enzyme bound Fe(II) to the inactive Fe(III) 
state. We concluded that TH activity may be severely limited by oxygen availability 
even at moderate hypoxic conditions, and that the enzyme is rapidly and turnover 
dependent inactivated at the experimental conditions commonly employed to measure 
in vitro activities. 
 
4.3 Article 3; Functional studies of tyrosine hydroxylase missense variants 
reveal distinct patterns of molecular defects in Dopa-responsive dystonia 
The reported clinical manifestations of THD are highly variable, with different levels 
of severity, age of onset and symptom profile. We collected clinical and biochemical 
data for all variants described in the literature at the start of the project. Thereafter, we 
also generated mutant forms of TH that had not previously been characterized 
biochemically in the literature, using site-directed mutagenesis and isoform 1 of human 
TH (TH1) as template. All TH mutants were expressed in E. coli (BL21(D3) pLysS) 
and purified on a heparin-Sepharose column. We compared the in vitro solubility, 
thermal stability, and kinetic properties of the TH variants to determine the cause(s) of 
their impaired enzyme activity. Interestingly, some TH variants had specific kinetic 
anomalies; and phenylalanine hydroxylase, and L-DOPA oxidase activities were 
measured for variants that showed signs of altered substrate binding. We found shifted 
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substrate specificity from tyrosine to phenylalanine and L-DOPA for the TH mutants 
p.Arg233His, p.Gly247Ser, and p.Phe375Leu, whereas p.Cys359Phe had an impaired 
activity toward these substrates. The great heterogeneity in solubility, stability and 
enzymatic activity of the mutated forms of TH, indicates that different pathogenic 
mechanisms may be involved in the neurological syndromes related to THD.   
 
5 General discussion 
5.1 Activity assays of tyrosine hydroxylase 
As described in the introduction, several assay methods for studying the activity of TH 
have been developed. Prior to the availability of recombinant enzyme, challenges 
concerning low enzyme availability and low enzyme activity in tissue homogenates 
caused the activity assays to mainly rely on spectrophotometric or other more sensitive 
procedures, using 3H- or 14C-labeled substrates or measuring product formation by 
HPLC with electrochemical or fluorometric detection (Haavik and Flatmark, 1980; 
Hooper et al., 1997; Kappock and Caradonna, 1996; Vrana et al., 1993). An oxygraphic 
method using a Gilson electrode to measure the oxygen consumption in the enzyme 
reaction has been published earlier (Shiman et al., 1971). However, this method had a 
low time resolution (5-8 min. between recordings) and has been criticized for low 
sensitivity by other researchers (Blank and Pike, 1976). As the oxygen consumption in 
enzymatic reactions of AAHs can provide additional mechanistic information, and is 
relevant in pathogenic mechanisms, we developed an oxygrapic assay (Article 1) using 
the Oroboros Oxygraph 2k, originally manufactured for monitoring oxygen 
consumption in mitochondria and cell preparations (Gnaiger, 2001; Hutter et al., 2004). 
Compared to the radiochemical and HPLC based assay methods, our oxygrapic assay 
has a relatively low sensitivity and throughput. However, it has given mechanistic and 
kinetic information previously unknown, such as new insight into the initial phase of 
the enzymatic reaction of the AAHs. Furthermore, combining measurement of the 
oxygen consumption and product formed in the enzyme reaction is necessary for 
uncovering “uncoupled” catalysis, particularly relevant for studying disease associated 
mutations.  
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5.2 Oxygen dependence of TH and production of ROS  
Availability of molecular oxygen is essential for respiration in all animal tissues and 
many lower organisms. Similarly, oxygen is a substrate for many biosynthetic 
reactions. In our study of the oxygen dependence of TH (Article 2), we found that the 
enzyme is rapidly inactivated at the experimental conditions usually employed to 
measure in vitro activities. We demonstrated high initial reaction rates in the hTH 
reaction, with initial Km’-values indicating that the enzymatic activity may be severely 
limited by oxygen availability under such conditions. Moreover, we have described a 
turnover dependent inactivation of the enzyme using several independent assay 
procedures. The transition from the high to the low-activity phase could either be due 
to a slow conformational change or a modification of the enzyme, e.g. by oxidation of 
the active site iron, with accumulation of an inactive Fe(III) state (Chow et al., 2009; 
Frantom et al., 2006), or by oxidation of redox sensitive amino acid residues. Evidence 
for both types of reactions has previously been presented for TH and other pterin 
dependent hydroxylases (Wallick et al. 1984; Ramsey et al. 1996; Kuhn et al. 1999). 
During catalytic turnover, the regeneration of enzyme bound Fe(II) may become 
kinetically limiting. Thus, Frantom et al. have calculated the half-life of reduction of 
Fe(III)TH by BH4 to be 3-5 s under physiological conditions (Frantom et al., 2006). 
We studied the effects of the  Fe(III) chelator desferrioxamine on the TH reaction, 
observing a time dependent inhibition of the enzyme similar to the observations of  
Ramsey et al. (Ramsey et al., 1996) using dihydroxynaphthalene on the rate of 
inactivation of rat TH. These findings indicate that a substantial amount of the active 
site Fe(II) is oxidized within the first 1-2 minutes of the enzyme reaction. As the kinetic 
burst cannot be overcome by increasing the exogenous concentrations of Fe(II), we 
suggest that it is the reduction of active site Fe(III), rather than incorporation of “new” 
Fe(II) that becomes rate limiting during the steady state TH reaction. 
 
As described in the introduction, the enzymatic reaction of the AAHs is dependent on 
the presence of a ferrous iron, correct sequence of binding and positioning of cofactor 
and substrates in the catalytic site. Of the THD associated mutations reported to date, 
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the C359F mutation, as one of 6 conserved cysteines in TH, is the mutation most likely 
to interfere directly in the catalytic site of TH. In our study (Article 3), we found that 
the C359F-TH mutant has a severely reduced activity compared to wt-TH (~10 %) and 
significantly altered affinities for both tyrosine and the cofactor BH4. Other catalytic 
domain variants of mutated TH also had altered properties; F375L-TH revealed a low 
specific activity (~ 10 % of compared to wt-TH) and a very low affinity towards 
tyrosine. Further investigation showed that the F375L-TH mutant had identical 
catalytic properties for phenylalanine hydroxylation as for tyrosine hydroxylation. The 
A376V-TH mutant had significantly reduced solubility compared to wt-TH, but had 
comparable substrate affinity and substrate inhibition constants. L387M-TH has 
solubility and activity comparable to wt-TH, but severely decreased thermal stability. 
The mutations I394T-TH and T399M-TH are also close to the active site, I394M-TH 
has severely reduced solubility and no measureable activity. T399M-TH has severely 
reduced activity and thermal stability. Active site mutations in the AAHs may interfere 
with normal reaction mechanism, producing toxic by-products. Excess oxygen 
consumption in the enzyme reaction can lead to formation of reactive oxygen species 
(ROS) (Haavik et al., 1997). We found no evidence for excess oxygen consumption in 
the mutant TH forms in this study. However, formation of ROS can be a pathogenic 
mechanism in vivo, as proposed for PD (Haavik and Toska, 1998; Nakashima et al., 
2013). 
 
5.3 Pathophysiology of AAH and comparison to findings in this study  
Understanding the molecular events causing human disease is one of the great 
challenges in the post-genomic era. Generally, it is difficult to obtain strict genotype-
phenotype correlations, even for well-defined monogenic metabolic diseases 
(Weatherall, 2000). This can partly be explained by the existence of compensatory 
physiological mechanisms and that many genes/proteins interact to create the genetic 
background through which the genotype has to penetrate, thus forming the observed 
phenotype. An example of this is found in PKU, where a proposed protective 
mechanism for hyperphenylalaninemia is described in patients with a polymorphism 
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in a transaminase that increases the clearance of phenylalanine from the bloodstream 
(Treacy et al., 1996). 
 For THD, the establishment of a clear correlation of genotype and phenotype is further 
complicated by the small number of patients reported, and the fact that a majority of 
the patients are compound heterozygous for mutations in the TH gene. Moreover, 
homozygosity of the p.Arg233His mutation has been reported in six type A and three 
type B patients. The p.Leu236Pro mutation occurred homozygously in one type A and 
two type B patients. However, all patients with at least one promoter mutation had the 
type A THD, indicating that some TH protein was produced, despite the presence of 
the promoter mutation. In THD patients born of consanguine parents, there is also an 
increased risk of other autosomal recessive traits/diseases that can complicate the 
clinical symptoms. There has nevertheless been reported a correlation between some 
biochemical phenotypic markers, as the CSF HVA content in the patients and the 
severity of their THD, based in their A and B-type classification (Willemsen et al., 
2010). A strong correlation between the activity of the mutants and CSF HVA content 
was found in our study. Thus, we also obtained a relationship between the remaining 
activity and the THD subtype (A and B) of the patients (Article 3). In the recently 
published studies of THD mouse models, the phenotype is homogeneous in the 
homozygous mice, probably reflecting the genetic background homogeneity of the 
inbred strain of mice used for genetic studies. Human patients, even homozygous for 
mutations in TH, have a higher phenotypic variability (Willemsen et al., 2010), 
suggesting a possibility for THD as a complex trait autosomal recessive disorder.  
In their study of the knock-in mouse model of THD type A carrying the homozygous 
mouse Th p.Q382K, Rose et al. (Rose et al., 2015) demonstrated reduced TH activity 
in vivo corresponding to the activity measured for the purified recombinant hTH1 
p.Q381K in vitro of ~ 15 % compared to wild type enzyme in brain regions containing 
mainly cell soma. Interestingly, in the axon terminal regions the TH activity was 
severely reduced (~ 1 % of wild type) possibly reflecting the reduced content of TH 
enzyme in the axon terminals. 
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Korner et al. have studied the THD type B associated mouse Th p.R203H mutation 
(corresponding to human TH1-p.R202H) knock-in mouse; a model of the most 
frequently occurring mutation found in human THD. The mice display a phenotype of 
severe dystonia with diurnal fluctuations, growth retardation despite normal calorie 
intake and respiratory exchange ratio, and no relief of symptoms upon administration 
of L-DOPA. A distinct absence of TH protein was observed in the striatum of this 
mouse model, as for the former.  
To date, no animal model of THD carrying TH mutations biochemically characterized 
in our study has been investigated, although both the p.R202H and the p.Q381K 
mutations were reviewed in Article 3. However, the present publications of THD 
knock-in mice models illustrates the value of knowledge of the biochemical 
characterization of mutated enzyme variants to explain in vivo effects and provide 
insights to focus research questions and areas of examination.  The reduced enzyme 
stability shown in in vitro studies of the hTH1-p.Q381K (Knappskog et al., 1995) and 
hTH1-p.R202H (Calvo et al., 2010; Korner et al., 2015) may indicate an explanation 
for the reduced transport of protein from the cell soma to the axon terminals, thus 
providing biochemical insight to the mislocalization of TH. Furthermore, in vivo 
examination of the consequences of altered substrate affinity and shift in substrate 
specificity of some of the mutated TH variants found in our study could elucidate 
disease processes still unknown and provide alternatives for specific therapeutic 
strategies. Dopamine deficiency, caused by degeneration of catecholaminergic neurons 
in PD or by primary THD, is usually treated by administration of L-DOPA or dopamine 
agonists. High levels of L-DOPA can even be neurotoxic and be oxidized to reactive 
intermediates, including quinones, semiquinones, and hydrogen peroxide (Kostrzewa 
et al., 2002). For the mutants of TH p.Arg233His, p.Gly247Ser, p.Phe375Leu and 
p.Gly414Arg, we observed a relatively increased efficacy of L-DOPA as substrate. 
Further investigation of these variants in vivo is necessary for determining if this poses 
an increased risk for a progressive course of neurological symptoms in patients 
harboring these mutations. Although the role of TH in the generation of neuromelanin 
and L-DOPA oxidation in vivo is not known, L-DOPA may be a better substrate for 
TH in vivo, as the enzyme appears to have a higher affinity for BH4 for conversion of 
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L-DOPA than for tyrosine hydroxylation (Haavik, 1997). We were not able to show an 
excess of oxygen consumption compared to product formation in the enzyme reaction; 
or any direct evidence for production of H2O2 in the THD associated TH variants in 
vitro.  
 
For PKU, a strict phenylalanine depleted diet has been the main treatment to date. 
However, some progress on alternative therapies has been made, based on the 
increasing knowledge of the molecular mechanisms of pathogenesis. Administration 
of BH4 as supplementary treatment was approved in 2007 (Kuvan®, in the form of 
sapropterin dihydrochloride), and has been efficient for some patients, leading to an 
increased tolerance for dietary phenylalanine (Levy et al., 2007). BH4 functions as a 
stabilizing agent (chaperone) for some variants of mutated PAH. For the BH4-
responsive PKU-patients this treatment alleviates the burden of strict diet requirement, 
and increases their quality of life (Blau and Erlandsen, 2004).  
5.4 Regulation of AAHs  
Mutations with total deleterious effect on the enzyme function are not expected in 
THD, as such mutations probably are not compatible with life, based on the essential 
role of TH in the development of the cardiovascular and nervous systems (Kobayashi 
et al., 1995). To date, no disease associated mutations in the AAHs in the highly 
conserved regulatory domain serine or threonine residues are reported. Mutations in 
this region will probably interfere with the intricate regulation of activity of the 
enzymes, and modify the phosphorylation and binding to regulatory molecules, like the 
14-3-3 proteins, of the AAH (Dunkley et al., 2004; Haycock, 1990; Haycock and 
Haycock, 1991; Kleppe et al., 2014; Miranda et al., 2002). Interestingly, in the study 
of the TH R202H knock-in mouse, the enzyme displayed deficient binding to 
catecholamines and was not stabilized by interaction with catecholamines, as expected 
for TH. As previously described, the TH R202 mouse has almost normal levels of TH 
in the substantia nigra, but deficiency of TH protein in the striatum, possibly reflecting 
the impact of the instability of the enzyme subjected to axonal transportation. This 
example illustrates that mutations of subtle effect on function and regulation requires 
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extensive investigation to understand the pathogenetic mechanisms and provide targets 
for treatment. 
6 Concluding remarks and future perspectives 
By investigating the oxygen dependence of the AAHs, their role in hypoxic conditions, 
e.g. the role of TH in altitude sickness and hypoxia induced hypertension as seen in 
OSAS, can be better understood and provide a basis for new therapeutic strategies. 
Studies of recombinant disease associated proteins, elucidating molecular mechanisms 
of disease, like the studies presented here, may contribute to advance individualized 
therapies for THD patients in the future. As current treatment of THD and Parkinson’s 
disease with L-DOPA supplement or dopamine agonists often are unable to provide 
lasting and adequate symptom relief, searches for treatments that directly target the 
malfunctioning TH are being conducted.  For PAH, the cofactor BH4 has a stabilizing 
effect, mainly as a pharmacological chaperone aiding correct folding of the protein 
(Underhaug et al., 2012). The stabilizing effect of BH4 for TH is less established. 
Searches for compounds with stabilizing effect on THD and PKU associated mutant 
protein have discovered a number of potential molecules; and are currently being tested 
on isolated enzymes, in cell culture and in animal models (Calvo et al., 2010; Hole et 
al., 2015; Hole et al., 2016). Different compounds had different mechanisms of 
protection of the activity of TH; both a classical chaperone stabilizing effect and a 
subgroup of compounds that preserved the activity of TH by weak binding to the 
catalytic site iron (Hole et al., 2015). Possibly, a synergistic effect can be achieved by 
combining different compounds for treatment of THD and PKU. 
Combining in vitro studies on recombinant enzyme, protein studies in the context of 
intact neuronal cell systems and animal model work for analyzing disease processes, 
our studies can be applicable not only to AAH-associated diseases, but also to other 
neurogenetic disorders, in which the stability and reaction mechanisms of mutant 
proteins are affected. If the protein of interest is required to be active in axons and 
dendrites, then pharmacological chaperones that promote the stable transport of the 
mutant protein to these regions could provide a valuable treatment option. Thus, 
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therapies in which pharmacological chaperones are used to stabilize mutant proteins 
are currently  being discussed as potential treatments for several neurogenetic disorders 
(e.g. lysosomal storage diseases (Parenti et al., 2015) and Friedreich's ataxia 
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